An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.
Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Dec 23, 2024
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment approach for patients with advanced colorectal cancer that has a specific genetic mutation called SMAD4R361H/C. The researchers want to see how well a combination of three drugs—Doxorubicin liposome, CapOX (which includes Oxaliplatin and Capecitabine), and Bevacizumab—works as a first-line treatment. They plan to enroll 13 participants who meet certain criteria, such as being 18 years or older, having confirmed advanced colorectal cancer that cannot be surgically removed, and having not received any prior chemotherapy.
Participants in this study will receive eight cycles of the treatment, and after that, their response will be assessed to see if they had a complete or partial response or if their disease remains stable. If their condition is evaluated positively, they will enter a maintenance phase. It’s important to note that the trial is not yet recruiting patients, and there are strict guidelines regarding who can participate, including health tests and no recent history of certain medical conditions. This ensures that the study is safe and that the results will be meaningful.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. The patient voluntarily participates in the study, signs the informed consent form, and demonstrates good compliance;
- • 2. Age 18 years or older (inclusive), regardless of gender;
- • 3. Histologically and/or cytologically confirmed unresectable colorectal adenocarcinoma;
- • 4. For left-sided colon cancer or rectal cancer patients, must be non-RAS wild-type;
- • 5. Non-dMMR/MSI-H;
- • 6. SMAD4R361H/C mutation;
- • 7. No prior history of systemic chemotherapy;
- • 8. ECOG performance status of 0 or 1;
- • 9. Hematological tests (within 14 days without blood transfusion): neutrophil absolute count ≥ 1.5 × 10⁹/L, platelet count ≥ 100 × 10⁹/L, hemoglobin ≥ 90 g/L;
- • 10. Liver function tests (AST and ALT ≤ 3 × ULN, bilirubin ≤ 1.5 × ULN; if liver metastasis is present, AST and ALT ≤ 5 × ULN);
- • 11. Renal function (serum creatinine ≤ 1.5 × ULN or creatinine clearance (CCr) ≥ 60 mL/min);
- • 12. Both male and female subjects of reproductive age must use effective contraception.
- Exclusion Criteria:
- • 1. Patients with known contraindications to Doxorubicin liposome, Oxaliplatin, Capecitabine, or Bevacizumab;
- • 2. Patients who have received radiotherapy or any anti-tumor treatments (chemotherapy, targeted therapy, immunotherapy, radiofrequency ablation, traditional Chinese medicine with anti-tumor indications, immunomodulators, or tumor embolization, etc.);
- • 3. Patients who have had other malignancies within the past 5 years or have concurrent malignancies (except for cured skin basal cell carcinoma and carcinoma in situ of the cervix);
- • 4. Patients who have experienced significant clinical bleeding symptoms, obvious bleeding tendency, or hemoptysis within 3 months prior to treatment, or who have had venous/thrombotic events such as cerebrovascular accidents (including transient ischemic attacks, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism within the previous 6 months; or require long-term anticoagulation treatment with warfarin or heparin, or require long-term antiplatelet therapy (aspirin ≥300 mg/day or clopidogrel ≥75 mg/day);
- • 5. Patients with active cardiovascular diseases within 6 months before treatment, including myocardial infarction, severe/uncontrolled angina. Echocardiography showing left ventricular ejection fraction \<50%, or poorly controlled arrhythmia;
- • 6. Known history of primary immunodeficiency virus infection;
- • 7. Patients with active or uncontrolled severe infections;
- • 8. Any other disease, clinically significant metabolic abnormalities, physical examination abnormalities, or laboratory test abnormalities, and based on the investigator's judgment, there is reasonable suspicion that the patient has a condition or disease that is unsuitable for the use of the study drug;
- • 9. Any situation that, in the investigator's opinion, could pose a risk to the patient receiving study drug treatment, interfere with the assessment of the study drug's safety, or affect the interpretation of results.
About Nanfang Hospital, Southern Medical University
Nanfang Hospital, affiliated with Southern Medical University, is a leading medical institution in China renowned for its comprehensive clinical services and commitment to advancing healthcare through research and education. As a clinical trial sponsor, Nanfang Hospital leverages its state-of-the-art facilities and a multidisciplinary team of expert researchers to conduct innovative studies aimed at improving patient outcomes and contributing to the global medical community. The hospital's focus on ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and scientific rigor.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported